Simlukafusp Alfa Plus Atezolizumab With/Without BevacizumabThe novel immunocytokine simlukafusp alfa plus atezolizumab, with or without bevacizumab, demonstrated a manageable safety profile and antitumor activity in patients with unresectable, mRCC.However, the doublet and triplet regimens did not improve response rates compared with standard therapies.Pharmacodynamic results confirmed the ability of IL-2–based therapies to induce an inflammatory infiltrate, supporting continued research of IL-2–based therapies and other novel immunocytokines in mRCC.
67 words · extracted 2mo agoread original ↗
comments(0)
5-min edit window · permanent after that